Wikipedia -WSS

Wikipedia

author：focus 2025-10-03 00:07:45 - browse：5551

A person reaching for a bottle of lipitor. -- first opinion coverage from STAT — John Moore/Getty Images

The antibiotics crisis is a silent pandemic that threatens to knock modern society back into the medieval age of therapeutic leaches and serum therapy. A world where an accidental scratch in the rose garden can kill.

Why is the supply of new antibiotics so thin, and growing thinner? A high-profile Wall Street Journal article recently highlighted what everyone knows: There is huge need but no market demand.

There are many interrelated causes. Doctors prefer to keep novel antibiotics in reserve, as a last-resort option, limiting sales volumes. Insurance companies like novel antibiotics that prevent costly ICU stays, but they’re used to the cheap price of older generics and balk at any price that allows recoupment of the full cost of development. Low prices and small volumes are a great recipe for insolvency as Achaogen’s experience showed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Violet CEO on training clinicians to promote more inclusive care

WSS

The Pandemic Treaty must support building strong health systems

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Violet CEO on training clinicians to promote more inclusive care

With trial win, GSK could get blood cancer drug back on market

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

SNAP should offer more nutrition education

hotspot

Wikipedia

entertainment

Walensky prepares to leave CDC — and Congress — behind

Why health care costs have stayed mostly flat since 2010

Hepatitis C has a cure — but many Americans still lack access to it

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Heart attack and stroke risk calculators need revising

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Kaiser's Risant Health gobbled up Geisinger. Who is next?

How to save PrEP access — and even expand it

Why health care costs have stayed mostly flat since 2010

focus

With trial win, GSK could get blood cancer drug back on market

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Change Healthcare can notify patients about the breach, HHS says

Innovation in antibiotics is ailing. 'Brain drain' may kill it

At ASCO, AstraZeneca reports strong data for breast cancer drug

knowledge

hotspot

entertainment

focus